Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) shares traded down 1.7% during mid-day trading on Tuesday . The company traded as low as $1.58 and last traded at $1.76. 20,514 shares changed hands during trading, a decline of 16% from the average session volume of 24,454 shares. The stock had previously closed at $1.79.
Humacyte Stock Performance
The firm has a 50 day moving average price of $1.70 and a 200 day moving average price of $1.95.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Articles
- Five stocks we like better than Humacyte
- Buy P&G Now, Before It Sets A New All-Time High
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- What Are Dividend Challengers?
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- Best Stocks Under $10.00
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
